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Abstract 
Paragangliomas  are  rare  tumors  and  very
few cases of malignant vagal paraganglioma
with synchronous carotid body paraganglioma
have been reported. We report a case of a 20-
year old male who presented with slow growing
bilateral neck masses of eight years duration.
He had symptoms of dysphagia to solids, occa-
sional  mouth  breathing  and  hoarseness  of
voice. Fine needle aspiration cytology (FNAC)
performed where he lived showed a sinus his-
tiocytosis and he was administered anti-tuber-
cular  treatment  for  six  months  without  any
improvement  in  his  symptoms.  His  physical
examination  revealed  pulsatile,  soft  to  firm,
non-tender  swellings  over  the  anterolateral
neck confined to the upper-mid jugulo-diagas-
tric region on both sides. Direct laryngoscopy
examination revealed a bulge on the posterior
pharyngeal wall and another over the right lat-
eral  pharyngeal  wall.  Magnetic  resonance
imaging (MRI), 99mTc-labeled octreotide scan
and angiography diagnosed the swellings as
carotid body paraganglioma, stage III on the
right side with left-sided vagal malignant para-
ganglioma. Surgery was ruled out as a high
morbidity  with  additional  risk  to  life  was
expected due to the highly vascular nature of
the tumor. The patient was treated with radia-
tion therapy by image guided radiation  to a
dose of 5040cGy in 28 fractions. At a follow-up
at 16 months, the tumors have regressed bilat-
erally  and  the  patient  can  take  solids  with
ease.
Case Report
We report a case of a 20-year old male who
presented  in  June  2008  with  complaints  of
slowly growing bilateral neck masses of eight
years duration and pain over the right neck. It
was associated with dysphagia to solids, occa-
sional breathing and hoarseness of voice. He
had  taken  anti-tubercular  treatment  for  six
months where he lived without any improve-
ment  in  his  neck  swellings.  No  history  of
evening  rise  of  temperature,  hemoptysis,
hematemesis,  excessive  sweating,  hyperten-
sion,  tachycardia,  weight  loss  or  chronic
obstructive pulmonary disease was available.
Physical examination revealed pulsatile, soft
to firm, non-tender swellings over the antero-
lateral neck, confined to upper-mid jugulo-dia-
gastric region on both sides. The right-sided
mass  measured  8¥6  cm  size  while  the  left-
sided mass was 3¥2 cm. Both the masses were
vertically  fixed  and  laterally  mobile  with  the
normal  overlying  skin.  Direct  laryngoscopy
examination revealed a bulge on the posterior
pharyngeal wall and another over the right lat-
eral pharyngeal wall. Atrophy of the left side of
the tongue with fibrillation was noted. No other
cranial nerve deficit could be elicited and sys-
temic examination was non-contributory. His
reports  from  the  previous  hospital  showed  a
cytopathological diagnosis of sinus histiocyto-
sis (Rosai Dorfman disease).
Neck MRI showed large lobulated, intensely
enhancing  bilateral  neck  masses  with  the
lesion  on  the  right  side  splaying  the  right
external  carotid  artery  (ECA)  and  internal
carotid artery (ICA) and engulfing the common
carotid artery (CCA) and ICA (Figure 1). The
right  side  lesion  extended  from  the  level  of
cricoid  cartilage  to  the  greater  wing  of  the
sphenoid. The lesion on the left side displaced
the ICA and ECA anteriorly. It was higher up
than the right sided lesion and extended from
the level of the left common carotid bifurcation
to the base of the skull, focally involving the
dura at the level of the cerebellar tonsils. The
lesion on the right side was compressing the
oropharynx and hypopharynx. Bilateral level III
and IV neck nodes were seen, the largest on
the right side measuring 11.5 mm and on the
left  side  measuring  11  mm.  99mTc-labeled
octreotide  scan  showed  regions  of  intense
focal uptake in the neck bilaterally and a small
satellite lesion with more intense uptake was
seen just below the mass on the left side, most
likely to be a lymph node (Figure 2). Twenty-
four  hour  urinary  metanephrine  levels  were
not elevated.
All  the  above  findings  were  suggestive  of
bilateral  paraganglioma  (carotid  body  tumor
on right side, stage III according to Shamblin’s
classification
1 and  malignant  vagal  paragan-
glioma  on  the  left  side  with  lymph  node
involvement). 
The case was discussed by the tumor board
made up of cardiothoracic surgeons, head and
neck surgeons, radiologist, nuclear medicine
specialist,  pathologist  and  radiation  oncolo-
gist. Surgery was ruled out as the bilateral two
stage procedure would have involved internal
carotid shunting resulting in multiple cranial
nerve deficits with additional risk to life. The
vascular surgeon did not agree to sclerosis of
the feeder vessels as the tumors were bilateral
and the possibility of active surgical interven-
tion for complete resection even after sclerosis
appeared  remote.  The  final  decision  was  to
offer  external  beam  radiation  to  this  large
lesion with the intent of reducing its vascular-
ity by causing radiation induced endarteritis
obiliterans and to consider surgical interven-
tion 12-18 months after radiotherapy for resid-
ual disease. 
Informed written consent for radiation ther-
apy was obtained. After performing a planning
CT-scan,  target  volumes  and  organs  at  risk
were contoured on a Tomocom work-station.
Bilateral gross disease including visible lymph
nodes were contoured as gross tumor volume
(GTV). The clinical target volume (CTV) was
contoured by giving a 1.5 cm margin to GTV. A
margin of 3 mm from CTV was enlarged for
planning target volume (PTV). Planning was
performed  on  a  Precise  treatment  planning
system and a dose of 5040cGy in 28 fractions
was  prescribed  to  PTV.  Isocentric  coplanar
intensity  modulated  treatment  (IMRT)  plan
with 8 portals and 31 segments was generated
and D95% of 4700cGy was obtained surround-
ing the PTV (Figure 3). After plan evaluation,
radiation was delivered by image guided radia-
tion therapy technique (IGRT) from 24th July
to 30th August 2008 on an Elekta Synergy lin-
ear accelerator. The patient tolerated radiation
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well with grade II mucositis in oropharynx that
was managed with topical analgesics. 
At  first  follow-up  at  three  months,  the
patient  reported  only  minimal  relief  in  his
symptoms.  On  examination  there  was  mild
regression  in  the  bilateral  neck  masses.  On
MRI, the mass on the left side measured 4.5 cm
(transverse) ¥ 2.8 cm (AP) ¥ 6.6 cm (CC) and
the right-sided mass was 7.4 cm (Transverse)
¥ 5.6 cm (AP) ¥ 9 cm (CC), suggestive of sta-
ble disease according to RECIST criteria.
2 On
second follow-up in June 2009, there was sig-
nificant subjective improvement in symptoms
of dysphagia, hoarseness and mouth breath-
ing. Neck examination showed a decrease in
the right-sided neck mass with fullness on the
left side of the neck without any discrete palpa-
ble lesion. MRI showed mass on the right side
of 7.5 cm (Tr.) ¥ 5.7cm (AP) ¥ 8.9 cm (CC) and
on the left side it was 3.9 cm (Transverse) ¥
3.4 cm (AP) ¥ 6.2 cm (CC). This was evaluated
as stable disease on both sides (Figure 4). On
99mTc-labeled octreotide scan, intensity was
less in the bilateral neck masses and the lymph
node was much less prominent.
At 16 months post treatment, the patient is
able to take solids with ease and clinically no
external  masses  are  palpable  in  the  neck.
Oropharyngeal examination shows a healthy
mucosa with no para-pharyngeal bulge.
Discussion
Paraganglia are part of the diffuse neuroen-
docrine  system  which  are  widely  dispersed
aggregates of neuroendocrine tissues located
near nerves and vessels.
3 They arise from neu-
ral crest progenitor cells and migrate along the
branchial  mesoderm  in  head  and  neck.
Paraganglioma or tumors of paraganglia arise
from this specialized tissue. Within the head
and neck, common sites are carotid body at
CCA  bifurcation,  jugular  foramen  along  the
vagus  nerve  and  within  the  middle  ear.
4
Paragangliomas  of  head  and  neck  are  rare
tumors, accounting for only 0.012% of all head
neck tumors
5 of which the carotid body is the
most common site. Vagal paraganglioma repre-
sent less than 5% of all the cases.
6 Bilateral
paragangliomas  are  much  less  common  and
malignancy in paraganglioma is even rarer (3-
6%).
7 Few  cases  of  synchronous  bilateral
carotid  body  and  vagal  paraganglioma  have
been reported in literature but we were not
able to find synchronous bilateral carotid body
paragangliona  (CBP)  and  malignant  vagal
paraganglioma managed by radiation therapy.
CBP  commonly  arise  along  the  postero-
medial  wall  at  the  CCA  bifurcation  but  may
also be located along either the ECA or ICA.
4
They are slow growing tumors with a mean
growth rate of 5 mm/year
8and a mean doubling
time of 4.2 years. Vagal body paraganglioma
most  commonly  arise  from  the  inferior
(nodose)  ganglion  but  may  also  arise  from
superior and middle ganglion and are typically
more cephalad than carotid body tumors.
6 Most
authorities regard extension to regional lym-
phnode or distant metastasis as the only reli-
able indicators of malignancy
9 as histopatho-
logical examination of the tumor is unreliable
for establishing a malignant diagnosis.
CBP  almost  always  presents  as  palpable
antero-lateral neck mass, located at or superi-
or to carotid bifurcation and deep to the ster-
nomastoid muscle
10 and some cases may pres-
ent with a pain in the mass. Incisional biopsy
is contraindicated due to the risk of hemor-
rhage.
11 MRI is superior to CT for soft tissue
details,  dura  and  neural  involvement.
12 CBP
causes splaying of the common carotid bifurca-
tion and displaces the ICA posteriorly and lat-
erally.  On  T2-weighted  images,  the  classical
“salt  and  pepper”  appearance  is  seen.
13
Octreotide  scintigraphy  is  a  non-invasive
modality which demonstrates an accuracy of
90%, sensitivity of 94% and specificity of 75%.
14
Vagal  paraganglioma  also  presents  as  slow
growing asymptomatic upper neck mass and
may involve the following nerves in decreasing
frequency: vagal, hypoglossal, spinal accessory
nerve. Sign and symptoms include hoarseness,
dysphagia, atrophy of the hemitongue, vocal
cord  palsy.  The  progression  of  symptoms  is
helpful in differentiating vagal paraganglioma
from  other  head  neck  paraganglioma.
15 Our
patient  had  symptoms  of  dysphagia,  hoarse-
ness and atrophy of left half of the tongue.
Surgical resection has been the mainstay of
the treatment for paraganglioma but surgery is
Case Report
Figure 1. Pre-treatment neck MRI showing
splaying of ICA, ECA on the right side by
CBP where as the vessels are pushed anteri-
orly on the left side by vagal paraganglioma.
Figure  4.  Neck  MRI  nine  months  post
treatment.
Figure  2.  Pre-treatment  99mTc-labeled
octreotide scan.
Figure 3. Irradiation portals with dose dis-
tribution showing 8 isocentrically placed
beams and coverage of PTV by 95% iso-
dose (color wash).
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relatively  contraindicated  in  extensive  skull
base  involvement  and  bilateral  or  multiple
paraganglioma that may result in unacceptable
post-operative morbidity and mortality. Lower
cranial nerve dysfunction is a common compli-
cation of surgical resection of head neck para-
ganglioma  and  bilateral  lower  cranial  nerve
palsies represent a severe life-threatening sit-
uation. Permanent cranial nerve deficit of 13%
to 40%
16,17 has been reported. Radiation therapy
is an effective therapeutic option especially in
the  management  of  unresectable  paragan-
glioma or if the surgery would result in signif-
icant  debility  requiring  long-term  rehabilita-
tion.
18 There is rarely total resolution of the
tumor after radiation therapy hence local con-
trol usually means stability of tumor size and
non-progression of neurological symptoms. 
In the last 40 years, most of the patients
have been treated with wedge pair or parallel-
opposed  field  setups  but  with  the  advent  of
conformal techniques, IMRT and fractionated
stereotactic radiotherapy (SRT) have become
preferred treatment methods. There seems to
be no significant difference among the radia-
tion treatment modalities in terms of tumor
control
19 but  the  conformal  techniques  can
exclude as many normal structures as possible
resulting  in  lesser  side  effects.  Kim  et  al.,
demonstrated that optimal dose appeared to be
greater than 40 Gy as local failure was 1% ver-
sus 25% for patients receiving more than 40Gy
versus less than 40 Gy, respectively.
20 Hinerman
et  al.  demonstrated  that  the  probability  of
tumor control with radiation does not appear to
depend on tumor size, at least when treated to
the recommended dose of 45Gy. We delivered a
dose of 5040cGy over 28 fractions with confor-
mal planning. 
In a review comparing results of radiation
with surgery, local control rates were compara-
ble to surgery, 72% versus 78%, although more
advanced lesions were treated with radiother-
apy.
21 In a retrospective study by Chino et al. of
31 patients of paraganglioma (14 after surgical
resection) treated between 1963 to 2005 with a
mean dose of 54Gy (38Gy-65Gy), the local con-
trol (LC) at five, ten and 15 years was 96%,
90% and 90%, respectively. There was no dif-
ference in LC between salvage radiation used
after surgical failure and definitive radiation
therapy, and there were no late radiation toxi-
cities  greater  than  grade  2.
22 Russel  et  al.
shared  a  35-year  experience  of  definitive
radiotherapy in 104 patients with 121 paragan-
gliomas treated between 1968 and 2004 where
89 paragangliomas were treated with conven-
tional  megavoltage  techniques,  15  paragan-
gliomas  with  stereotactic  fractionated  radia-
tion therapy, 6 paragangliomas with SRT and
11 paragangliomas with IMRT. There were 6
local recurrences and the actuarial local con-
trol  and  cause-specific  survival  rates  at  ten
years were 94% and 95% where as the overall
control rate for all 121 lesions was 95% and the
incidence  of  treatment  related  complication
was low.
19 Acute radiation complications usual-
ly seen are loss of taste, dryness of mouth, dys-
phagia, odynophagia and dermatitis which are
usually well tolerated with minimal long-term
toxicities like subcutaneous fibrosis, xerosto-
mia, and hypothyroidism.
Conclusions
Clinicians should have a high index of sus-
picion when a patient presents with pulsatile
neck mass and biopsy should not be attempted.
For  unresectable  tumors  or  high-risk  cases,
radiation  therapy  is  a  good  alternative  with
acceptable acute side effects and minimal late
complications.
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